Ftse Mib
38.421,05
0,00%
DAX
22.287,56
-0,24%
S&P 500
6.013,13
-1,71%
NASDAQ
19.524,01
-2,20%
Bitcoin
95.860,44
-0,43%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aquestive Therapeutics Inc (AQST) Aquestive Therapeutics Inc (AQST) Notizie

AQST

Aquestive Therapeutics (AQST)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AQST
DataOraFonteTitoloSimboloCompagnia
20/02/202513:00GlobeNewswire Inc.Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
15/02/202500:12Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
12/02/202513:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AQSTAquestive Therapeutics Inc
12/02/202513:00GlobeNewswire Inc.Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
04/02/202513:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
24/01/202522:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AQSTAquestive Therapeutics Inc
13/01/202513:00GlobeNewswire Inc.Aquestive Therapeutics Provides Business Update and Outlines Key 2025 ObjectivesNASDAQ:AQSTAquestive Therapeutics Inc
19/12/202414:00GlobeNewswire Inc.Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to FiveNASDAQ:AQSTAquestive Therapeutics Inc
02/12/202414:00GlobeNewswire Inc.Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
27/11/202422:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
14/11/202421:47Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
12/11/202414:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Two Upcoming Investor ConferencesNASDAQ:AQSTAquestive Therapeutics Inc
08/11/202423:31Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AQSTAquestive Therapeutics Inc
04/11/202422:36GlobeNewswire Inc.Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
25/10/202414:00GlobeNewswire Inc.Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American CollegeNASDAQ:AQSTAquestive Therapeutics Inc
24/10/202414:00GlobeNewswire Inc.Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
21/10/202414:00GlobeNewswire Inc.Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
02/10/202420:16Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
27/09/202414:30GlobeNewswire Inc.Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor DayNASDAQ:AQSTAquestive Therapeutics Inc
09/09/202414:15GlobeNewswire Inc.Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27thNASDAQ:AQSTAquestive Therapeutics Inc
14/08/202414:00GlobeNewswire Inc.Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™NASDAQ:AQSTAquestive Therapeutics Inc
06/08/202422:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AQSTAquestive Therapeutics Inc
06/08/202422:22GlobeNewswire Inc.Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
25/07/202414:00GlobeNewswire Inc.Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration StudyNASDAQ:AQSTAquestive Therapeutics Inc
23/07/202414:00GlobeNewswire Inc.Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
27/06/202414:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismNASDAQ:AQSTAquestive Therapeutics Inc
25/06/202414:00GlobeNewswire Inc.Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
18/06/202414:00GlobeNewswire Inc.Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024NASDAQ:AQSTAquestive Therapeutics Inc
12/06/202423:14Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
11/06/202418:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AQST

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci